title: The value of monitoring minimal residual disease in the patients with donor lymphocyte infusion as intervention of relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
authors.forename: Xiao
authors.initials: X
authors.lastname: Ma
authors.forename: Depei
authors.initials: D
authors.lastname: Wu
authors.forename: Aining
authors.initials: A
authors.lastname: Sun
authors.forename: Huiying
authors.initials: H
authors.lastname: Qiu
authors.forename: Zhenzhen
authors.initials: Z
authors.lastname: Fu
authors.forename: Xiaojin
authors.initials: X
authors.lastname: Wu
authors.forename: Suning
authors.initials: S
authors.lastname: Chen
authors.forename: Mohamad
authors.initials: M
authors.lastname: Mohty
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000473:pathology / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D017710:Lymphocyte Transfusion; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D018365:Neoplasm, Residual; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology / Q000628:therapy*; D012008:Recurrence; D014184:Transplantation, Homologous